

For Immediate Release

**CyGenics Ltd and Cell Therapies
to Collaborate on T-cell Clinical Trials**

10th NOVEMBER 2004 – Cytomatrix Pty Ltd, a subsidiary of the stem cell biotechnology and immunotherapy company CyGenics Ltd (ASX: CYN), and Cell Therapies Pty Ltd, the commercial manager of the Cell Processing Centre within the Centre for Blood Cell Therapies at Peter MacCallum Cancer Centre, announced that they will collaborate on Phase I and II clinical trials utilising CyGenics' patented cell production technology which generates T immune cells from stem cells outside the body for the first time. Under the agreement, Cell Therapies Pty Ltd will produce the T-cells using the technology for patients enrolled in the planned clinical trials.

The clinical trials are intended to demonstrate the safety and efficacy of T-cells produced in Cytomatrix's T-cell production technology. Clinical trials are anticipated to commence in Australia in 2005. The company sees these Phase I and II trials as on track for completion by mid-2006. The target patient group for these clinical trials will be patients with lymphoma and leukaemia and related diseases, for whom chemotherapy treatment has damaged their immune system. Under the protocol, blood stem cells and skin cells will be extracted from the patients, and grown in the Cytomatrix scaffold to produce new T-cells that will be transfused back into the patients.

As Australia's premier cancer centre, the Peter Mac is dedicated to the treatment of cancer patients. The Peter Mac is renowned for its expertise treating complex and rare types of cancers, as well as common cancers. The Peter Mac has also helped pioneer a multidisciplinary approach to cancer care, whereby experts in diagnostic imaging, chemotherapy, radiation therapy, surgery, immunotherapy and supportive care work together to tailor treatment plans for each patient, providing the best possible outcomes at every stage of illness.

A successful completion of these trials will place CyGenics among the first in the world to offer safe, efficacious and cost effective means of producing T-cells for therapeutic uses, addressing a key limitation in the treatment of patients whose immune systems have been damaged. The technology is expected to be applicable to a wide range of malignant diseases, infectious diseases and autoimmune disorders, including patients who have HIV or who have received chemotherapy and/or radiation treatment. As these trials near completion, CyGenics intends to develop T-cell production kits for immunotherapy for some diseases, as well as license this technology to research and pharmaceutical companies involved in developing treatments for other diseases.



“The successful development of this far-ranging technology will contribute significantly towards the ability to help reconstruct the immune system of patients who currently have few, if any, alternatives,” said Dr Mark Pykett, Chairman, Scientific Advisory Board. “These trials are in line with CyGenics’ goals of leveraging the excellent clinical expertise and stem cell therapeutic programs being established in Australia, and part of our long-term growth strategy for this market. We are indeed very pleased to have the highly respected institutions, Cell Therapies Pty Ltd and the Peter MacCallum Cancer Centre together with us in this endeavour.”

“As a key centre for adult cancer therapy, the Peter MacCallum Cancer Centre and Cell Therapies Pty Ltd have been conducting life-saving medical research and clinical trials on a wide variety of conditions that affect adults for more than 50 years,” said Professor Miles Prince, Chair of Haematology Service of the Peter Mac. “The potential of T-cell therapy to boost the immune system and reduce the risk of infections that occur following cancer treatment, is enormous. The primary limitation today is that there is no simple way to produce or replace T-cells that have been damaged by the treatment given to patients. We are excited to be working on trials that may well put an end to this limitation.”

About CyGenics

CyGenics is a biotechnology and immunotherapy company focused on the development and commercialisation of stem cell-related products, services, applications and technologies. From its headquarters in Australia, CyGenics operates three divisions: Singapore-based CordLife (tissue banking services, in particular, cord blood banking) and Cell Sciences (consumable cell culture products), and Cytomatrix (cell therapeutics and technology development) based in the USA. CyGenics is listed on the Australian Stock Exchange, under the symbol CYN. For more information, please visit www.cygenics.com.

About Cell Therapies

Cell Therapies Pty Ltd, (CT) is the commercial manager of the Centre for Blood Cell Therapies (CBCT) at Peter MacCallum Cancer Centre. CT is in the business of planning and conducting clinical trials that involve the collection, manipulation and storage of human blood cells and tissue. The services range from laboratory rental through to fully-integrated planning and execution of clinical trials that involve cellular therapeutics manufactured in code of Good Manufacturing Practice (cGMP) and Therapeutic Goods Administration (TGA) licensed facilities. For more information, please visit www.celltherapies.com.au.

For more information, please contact:

Ronald Hee
Corporate Communications &
Marketing Manager
CordLife Pte Ltd
600 North Bridge Road,
#12-09/10, Parkview Square,
Singapore 188778, Singapore
Tel : +65 6238 0808
Fax : +65 6295 1108
Mobile: +65 9061 9098
Email: rhee@cordlife.com

Mr Raymond Wood
Managing Director
Cell Therapies Pty Ltd
Ground Floor #10 St Andrew’s Place
East , Melbourne Victoria 3000
Australia
Tel: +613 9656 1615
Fax: +613 9656 1650
Mobile: +61 419 344 530
Email: rayjwood@celltherapies.com.au

Rod Nockles
Director
Financial & Corporate Relations
Level 20,
114 William Street
Melbourne Victoria 3000
Australia
Tel: +61 3 9670 7996
Fax: +61 3 9670 3883
Mobile: +61 (0) 419 691 323
E-mail: r.nockles@fcr.com.au